Filing Details
- Accession Number:
- 0000899243-19-029824
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-12-20 18:53:06
- Reporting Period:
- 2019-11-12
- Accepted Time:
- 2019-12-20 18:53:06
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1404644 | Neoleukin Therapeutics Inc. | NLTX | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1588467 | G Jonathan Drachman | C/O Neoleukin Therapeutics, Inc. 1616 Eastlake Avenue E., #360 Seattle WA 98102 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Series A Preferred Stock | Disposition | 2019-11-12 | 12,616 | $0.00 | 0 | No | 4 | C | Direct | |
| Common Stock | Acquisiton | 2019-11-12 | 1,261,600 | $0.00 | 2,079,639 | No | 4 | C | Direct | |
| Common Stock | Acquisiton | 2019-12-20 | 119,047 | $8.40 | 2,198,686 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Direct | |
| No | 4 | C | Direct | |
| No | 4 | P | Direct |
Footnotes
- Each share of Series A Convertible Preferred Stock converted into 100 shares of the Issuer's Common Stock upon the approval of the Issuer's stockholders on November 12, 2019.
- Represents shares purchased in an underwritten public offering of the Issuer's Common Stock.
Billionaire Hedge Funds
